AR062709A1 - Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt - Google Patents

Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt

Info

Publication number
AR062709A1
AR062709A1 ARP070103967A ARP070103967A AR062709A1 AR 062709 A1 AR062709 A1 AR 062709A1 AR P070103967 A ARP070103967 A AR P070103967A AR P070103967 A ARP070103967 A AR P070103967A AR 062709 A1 AR062709 A1 AR 062709A1
Authority
AR
Argentina
Prior art keywords
wnt
treatment
antagonists
gen
diagnosis
Prior art date
Application number
ARP070103967A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR062709A1 publication Critical patent/AR062709A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)

Abstract

La presente proporciona antagonistas quiméricos de Wnt que comprenden un componente del dominio Frz derivado de una proteína Frizzled, una proteína secretada relacionada con el receptor Frizzled o una proteína Ror y un componente de inmunoglobulina de Fc, y su uso en el tratamiento y deteccion diagnostica de los trastornos mediados por Wnt y la senalizacion celular Wnt, incluido cáncer.
ARP070103967A 2006-09-08 2007-09-07 Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt AR062709A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82506306P 2006-09-08 2006-09-08
US95117507P 2007-07-20 2007-07-20

Publications (1)

Publication Number Publication Date
AR062709A1 true AR062709A1 (es) 2008-11-26

Family

ID=39092004

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103967A AR062709A1 (es) 2006-09-08 2007-09-07 Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt

Country Status (19)

Country Link
US (5) US7947277B2 (es)
EP (1) EP2061495A2 (es)
JP (1) JP2010504081A (es)
KR (1) KR20090060334A (es)
AR (1) AR062709A1 (es)
AU (1) AU2007292242A1 (es)
BR (1) BRPI0714751A2 (es)
CA (1) CA2662041A1 (es)
CL (1) CL2007002609A1 (es)
CR (1) CR10699A (es)
IL (1) IL197240A0 (es)
MA (1) MA31135B1 (es)
MX (1) MX2009002522A (es)
NO (1) NO20091413L (es)
PE (3) PE20120807A1 (es)
RU (1) RU2009113023A (es)
SG (2) SG174100A1 (es)
TW (1) TW200819463A (es)
WO (1) WO2008031009A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2007053577A2 (en) * 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP2009065938A (ja) * 2007-09-14 2009-04-02 Matsumoto Shika Univ タンパク質、破骨細胞分化阻害剤、炎症性骨破壊治療薬、遺伝子、組み替えベクター、及びタンパク質の製造方法
US20100260785A1 (en) * 2007-12-13 2010-10-14 Gabriela Saborio SARP-1 Fusion Proteins and Uses Thereof
EP2274622B1 (en) 2008-04-30 2014-10-08 The Governing Council of the University of Toronto Use of sfrp-3 in the assessment of heart failure
ES2334092B1 (es) * 2008-07-02 2011-01-24 Proyecto De Biomedicina Cima, S.L. Agentes antiangiogenicos.
RU2579897C2 (ru) 2008-09-26 2016-04-10 Онкомед Фармасьютикалс, Инк. Агенты, связывающие рецептор "frizzled", и их применение
WO2010038756A1 (ja) * 2008-09-30 2010-04-08 協和発酵キリン株式会社 Frizzled1、Frizzled2又はFrizzled7細胞外システインリッチドメインを含む蛋白質を含有する骨疾患治療用医薬組成物
EP2421899B1 (en) 2009-04-23 2016-06-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-human ror1 antibodies
WO2010132532A1 (en) 2009-05-15 2010-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services B cell surface reactive antibodies
US20110189097A1 (en) * 2009-11-09 2011-08-04 Dritan Agalliu Use of WNT inhibitor to inhibit angiogenesis in the CNS
TWI535445B (zh) * 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
KR20130043102A (ko) 2010-04-01 2013-04-29 온코메드 파마슈티칼스, 인크. 프리즐드-결합 작용제 및 그의 용도
EP2585098B1 (en) * 2010-06-28 2014-08-27 Five Prime Therapeutics, Inc. Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
EP2630154A1 (en) 2010-10-20 2013-08-28 F.Hoffmann-La Roche Ag Methods and compositions for modulating the wnt pathway
CA2817975C (en) 2010-11-16 2020-03-31 Michael Kahn Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells
US9758586B2 (en) 2010-12-01 2017-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ROR1 antibodies
EP2720721B1 (en) 2011-06-17 2017-08-30 President and Fellows of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
WO2012176853A1 (ja) 2011-06-21 2012-12-27 協和発酵キリン株式会社 Ｆｒｉｚｚｌｅｄ２の細胞外領域蛋白質のトランケート体を含む蛋白質、および該蛋白質を含有する骨疾患治療用医薬組成物
CA2841745A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
US20130216546A1 (en) * 2012-01-10 2013-08-22 Ngm Biopharmaceuticals, Inc. Methods of Treating Glucose Metabolism Disorders
MX366804B (es) 2012-02-11 2019-07-25 Genentech Inc Translocaciones de la r-espondina y sus metodos de uso.
PT2817329T (pt) 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polipeptioos que se ligam ao complemento humano c5
AU2013334790A1 (en) * 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
WO2014096163A1 (en) * 2012-12-19 2014-06-26 Affibody Ab New polypeptides
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN105829547A (zh) 2013-12-02 2016-08-03 昂科梅德制药有限公司 与Wnt途径抑制剂有关的预测性生物标记物的鉴别
JP2017526641A (ja) 2014-07-11 2017-09-14 ジェネンテック， インコーポレイテッド Ｎｏｔｃｈ経路阻害
KR101572606B1 (ko) * 2014-11-24 2015-11-27 강원대학교산학협력단 Sfrp5 유래의 펩타이드 및 이를 포함하는 피부 미백용 화장료 조성물
WO2016126054A1 (ko) 2015-02-04 2016-08-11 (주)메드팩토 변형된 ｄｋｋ2 단백질 또는 그 유전자를 포함하는 발기부전 예방 또는 치료용 조성물 및 이를 이용한 방법
US10913786B2 (en) * 2016-03-21 2021-02-09 Children's Medical Center Corporation Compositions and methods for inhibiting Wnt signaling
CN108310366A (zh) * 2017-01-15 2018-07-24 复旦大学附属华山医院 重组sfrp5蛋白在制备治疗非酒精性脂肪性肝炎药物中的用途
KR20220113951A (ko) * 2019-11-18 2022-08-17 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 항-ror-2 항체 및 사용 방법
EP4065599A4 (en) * 2019-11-26 2023-11-01 Cedars-Sinai Medical Center COMPOSITIONS AND METHODS FOR TREATING ILLNESSES AND CONDITIONS BY REMOVING MITOCHONDRIAL OR GENOMIC DNA FROM THE CIRCULATION

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039357A1 (en) * 1996-04-12 1997-10-23 The Board Of Trustees Of The Leland Stanford Junior University Wnt RECEPTOR COMPOSITIONS AND METHODS
JP4299886B2 (ja) * 1996-09-24 2009-07-22 タノックス インコーポレイテッド アポトーシス関連ペプチドをコードする遺伝子ファミリー、それによってコードされるペプチド、およびそれらの使用方法
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2001058957A2 (en) * 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
AU2001272974A1 (en) 2000-06-21 2002-01-02 Incyte Genomics, Inc. Human receptors
US7413873B2 (en) * 2001-01-30 2008-08-19 The Regents Of The University Of California Method of detection and treatment of colon cancer
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US7682607B2 (en) * 2001-05-01 2010-03-23 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
AU2002317105A1 (en) 2001-07-05 2003-01-21 University Of British Columbia Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
AU2002337657A1 (en) * 2001-07-25 2003-02-17 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
CA2501235A1 (en) * 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
US7803783B2 (en) * 2002-12-06 2010-09-28 The Board Of Trustees Of The Leland Stanford Junior University Use of WNT inhibitors to augment therapeutic index of chemotherapy
JP2006508682A (ja) * 2002-12-06 2006-03-16 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ β−カテニンシグナル伝達経路の調節による細胞傷害剤からの幹細胞の保護
US20050096263A1 (en) * 2003-10-30 2005-05-05 Keay Susan K. Novel antiproliferative factor and methods of use
WO2006036175A2 (en) 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Wnt proteins and detection and treatment of cancer
EP1805519B1 (en) 2004-09-21 2013-11-06 Rhode Island Hospital Wnt proteins and detection and treatment of cancer
US7867705B2 (en) * 2004-09-21 2011-01-11 Rhode Island Hospital, A Lifespan-Partner Frizzled proteins and detection and treatment of cancer
JP2008520583A (ja) 2004-11-15 2008-06-19 マウント シナイ スクール オブ メディスン オブ ニューヨーク ユニバーシティー Ｗｎｔ自己分泌シグナル伝達を改変するための組成物および方法
US7723477B2 (en) * 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth

Also Published As

Publication number Publication date
CA2662041A1 (en) 2008-03-13
MA31135B1 (fr) 2010-02-01
CR10699A (es) 2009-07-10
US20100266593A1 (en) 2010-10-21
WO2008031009A3 (en) 2009-07-02
RU2009113023A (ru) 2010-10-20
PE20120806A1 (es) 2012-07-25
US20110311534A1 (en) 2011-12-22
CL2007002609A1 (es) 2008-04-18
BRPI0714751A2 (pt) 2014-06-24
US20120141481A1 (en) 2012-06-07
NO20091413L (no) 2009-06-08
KR20090060334A (ko) 2009-06-11
AU2007292242A1 (en) 2008-03-13
WO2008031009A2 (en) 2008-03-13
US7947277B2 (en) 2011-05-24
EP2061495A2 (en) 2009-05-27
US20080299136A1 (en) 2008-12-04
MX2009002522A (es) 2009-06-19
SG174101A1 (en) 2011-09-29
PE20120807A1 (es) 2012-07-26
SG174100A1 (en) 2011-09-29
TW200819463A (en) 2008-05-01
IL197240A0 (en) 2011-08-01
JP2010504081A (ja) 2010-02-12
PE20081217A1 (es) 2008-09-24
US20170349639A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
AR062709A1 (es) Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt
PE20190115A1 (es) Anticuerpos vista antihumanos y su uso
PA8782201A1 (es) Anticuerpo humanizados contra el globulómero ab(20-42) y sus usos
ECSP088835A (es) Terapia combinatoria que involucra antagonistas de alfa5beta1
WO2008055257A3 (en) Cartridge for conducting diagnostic assays
DOP2010000211A (es) Formas cristalinas del dimetoxi-docetaxel y sus procedimientos de preparacion
CR11042A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
CL2008001826A1 (es) Metodos y composicion para el tratamiento de enfermedades alergicas anticuerpo anti-receptor de linfopoyetina estromal timica humana (tslp) o porcion de enlace de antigeno del mismo; polinucleotido que lo codifica; celula huesped; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o trastorno inflamatorio en un sujeto
EA201171081A1 (ru) Производные индола в качестве антагонистов рецептора crth2
CL2011000230A1 (es) Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
CL2012002771A1 (es) Compuestos derivados de ariletinilo sustituidos, moduladores de los receptores mglur5; proceso de obtencion; composicion farmaceutica; y su uso en el tratamiento o prevencion de la esquizofrenia, enfermedades cognitivas, sindrome de x fragil o el autismo.
GT201000037A (es) Depsipéptidos cíclicos
CR11504A (es) Deteccion mejorada de la expresion de mage-a
DOP2009000102A (es) Anticuerpos del agonista trkb y usos de los mismos
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
CO6761356A2 (es) Anticuerpos anti receptr 4 de quimiricina cc (ccr4) y usos de los mismos
ATE517106T1 (de) Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
ATE542139T1 (de) Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
CR20110034A (es) Peptidos de señalizacion de la crkl
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
MX2022010954A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
MX2021007951A (es) Ensayo multiplexado y metodos de uso del mismo.
AR072136A1 (es) Metodos de tratamiento que utilizan proteinas de union del receptor de in-terleuquina 21
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal